Research programme: anorectants - Abbott/TularikAlternative Names: Anorectants research programme - Abbott/Tularik; Antiobesity agents research programme - Abbott/Tularik; Research programme: antiobesity agents - Abbott/Tularik
Latest Information Update: 11 Dec 2001
At a glance
- Originator Abbott GmbH & Co. KG; Tularik
- Developer Tularik
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 11 Dec 2001 Discontinued-Preclinical for Obesity in USA (Unknown route)
- 18 Jun 2001 Knoll notified Tularik that it is terminating the collaboration in obesity from October 31, 2001
- 13 Mar 2001 BASF's pharmaceutical business has been acquired by Abbott Laboratories